Results 61 to 70 of about 231,281 (308)

An Overview of Repurposed Drugs for Potential COVID-19 Treatment

Antibiotics, 2022
The COVID-19 pandemic caused by SARS-CoV-2 has placed severe constraints on healthcare systems around the globe. The SARS-CoV-2 virus has caused upheaval in the healthcare and economic sectors worldwide. On the 20th of May 2020, the World Health Organisation declared COVID-19 a global pandemic due to the unprecedented number of cases reported around ...
Kamini Govender, Anil Chuturgoon
openaire   +3 more sources

Drug-drug interactions between COVID-19 therapeutics and psychotropic medications

, 2023
IntroductionThe coronavirus (COVID-19) pandemic has led to as well as exacerbated mental health disorders, leading to increased use of psychotropic medications.
Spiti, Alessandro, Cuomo, Alessandro, Serafini, Gianluca, Barillà, Giovanni, Cattolico, Matteo, Carmellini, Pietro, Amerio, Andrea, Fagiolini, Andrea, Aguglia, Andrea   +8 more
core   +1 more source

Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options

Molecular Therapy: Methods & Clinical Development, 2020
The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected number keeps increasing.
Boxuan Huang, Rongsong Ling, Yifan Cheng, Jieqi Wen, Yarong Dai, Wenjie Huang, Siyan Zhang, Xifeng Lu, Yifeng Luo, Yi-Zhou Jiang   +9 more
doaj   +1 more source

Role of monoclonal antibody drugs in the treatment of COVID-19

World Journal of Clinical Cases, 2020
Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress syndrome that can lead to death infected patients.
Ucciferri C., Vecchiet J., Falasca K.
openaire   +3 more sources

Rational drug repositioning for coronavirus-associated diseases using directional mapping and side-effect inference

iScience, 2022
Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen of coronavirus disease 2019 (COVID-19), has infected hundreds of millions of people and caused millions of deaths.
Jianhua Wang, Jiaojiao Liu, Menghan Luo, Hui Cui, Wenwen Zhang, Ke Zhao, Hongji Dai, Fangfang Song, Kexin Chen, Ying Yu, Dongming Zhou, Mulin Jun Li, Hongxi Yang   +12 more
doaj   +1 more source

Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID‐19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug ...
Pattara Rattanawong, Win Shen, Hicham El Masry, Dan Sorajja, Komandoor Srivathsan, Arturo Valverde, Luis R. Scott   +6 more
doaj   +1 more source

Recommendations for the outpatient drug treatment of patients with COVID-19

Deutsches Ärzteblatt international, 2022
One of the purposes of outpatient treatment for COVID-19 patients is to prevent severe disease courses and hospitalization. There is a need for evidence-based recommendations to be applied in primary care and specialized outpatient settings.This guideline was developed on the basis of publications that were retrieved by a systematic search for ...
Kaduszkiewicz, Hanna, Kochen, Michael M., Kluge, Stefan, Malin, Jakob J., Weibel, Stephanie, Skoetz, Nicole   +5 more
openaire   +4 more sources

Safety perspectives on presently considered drugs for the treatment of COVID‐19 [PDF]

British Journal of Pharmacology, 2020
Intense efforts are underway to evaluate potential therapeutic agents for the treatment of COVID‐19. In order to respond quickly to the crisis, the repurposing of existing drugs is the primary pharmacological strategy. Despite the urgent clinical need for these therapies, it is imperative to consider potential safety issues.
Sophie Penman, Robyn Kiy, Rebecca Jensen, Christopher Beoku-Betts, Ana Alfirevic, David Back, Saye Khoo, Andrew Owen, Munir Pirmohamed, Kevin Park, Xiaoli Meng, Christopher Goldring, Amy Chadwick   +12 more
openaire   +3 more sources

A Case Series: Successfully Preventing COVID-19 Outbreak in a Residential Community Setting at a Drug and Alcohol Addiction Treatment Center

, 2021
Coronavirus disease 2019 (COVID-19) has reduced the capacity of many addiction treatment centers, limiting access to safe, continual treatment for people with substance use disorders (SUD) in the setting of a pandemic.
Douglas McHugh, Kenneth Hanton, Gregory Boris   +2 more
core   +1 more source

Available Drugs and Supplements for Rapid Deployment for Treatment of COVID-19 [PDF]

Journal of Molecular Cell Biology, 2020
Effective treatment for COVID-19 remains elusive, though urgently needed in the current pandemic. Repurposing marketed therapies may be an effective strategy for finding therapies quickly and recently in vitro and clinical testing of such therapies against SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) has skyrocketed.
Cicka, Danielle, Sukhatme, Vikas P
openaire   +2 more sources